Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSK | P41240 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 2/20 | 0.43 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.43 |
| ▸ | CIT | O14578 | 1/20 | 0.43 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4934030 | 1.00 | CSK (0.56) | CSKSMN1; SMN2HDAC8MAPTROCK2 | |
| SCHEMBL4934979 | 0.86 | CSK (0.60) | CSKSMN1; SMN2HDAC8MAPTROCK2 | |
| SCHEMBL4934991 | 0.86 | CSK (0.60) | CSKSMN1; SMN2HDAC8MAPTROCK2 | |
| SCHEMBL2994486 | 0.84 | BACE1 (0.57) | SMN1; SMN2HDAC8ROCK2NPC1RAB9A | |
| SCHEMBL2994483 | 0.84 | BACE1 (0.57) | SMN1; SMN2HDAC8ROCK2NPC1RAB9A | |
| SCHEMBL24514045 | 0.83 | LNPEP (0.50) | SMN1; SMN2HDAC8ROCK2NPC1RAB9A | |
| SCHEMBL4930575 | 0.81 | CSK (0.55) | CSKHDAC8MAPTROCK2BACE1 | |
| SCHEMBL4930592 | 0.81 | CSK (0.55) | CSKHDAC8MAPTROCK2BACE1 | |
| SCHEMBL29145376 | 0.79 | LNPEP (0.46) | SMN1; SMN2HDAC8ROCK2BACE1LNPEP | |
| SCHEMBL24514069 | 0.79 | LNPEP (0.46) | SMN1; SMN2HDAC8ROCK2BACE1LNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132539-A1 | Hydroxamic Acid Derivative And Age Generation Inhibitor Containing The Derivative | KUREHA CORPORATION (JP) | 2008-06-05 | — | — | US | disclosed |
| EP-1707560-A1 | HYDROXAMIC ACID DERIVATIVE AND AGE GENERATION INHIBITOR CONTAINING THE DERIVATIVE | Kureha Corporation (JP) | 2006-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132539-A1 | Hydroxamic Acid Derivative And Age Generation Inhibitor Containing The Derivative | HDAC5, HDAC1, HDAC9 | CSK 2328/4885SMN1; SMN2 3068/4885HDAC8 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.